Challenges With CAR T-Cell Therapy
During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.
During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, assistant professor of medicine, division of hematology and oncology, Vanderbilt University Medical Center, discusses some of the challenges he has encountered with chimeric antigen receptor (CAR) T-cell therapy.
Oluwole says that many patients have progressive disease and need chemotherapy while the CAR T-cell therapy is being produced, as their disease tends to grow quickly. Currently, there are 2 commerically-approved products for patients with large B cell lymphoma: axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah). Giving one of these agents to bridge the gap in therapy is a way of keeping the patient's disease controlled while the insurance approval is ongoing or the product is being manufactured.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
